Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor‑β receptor I kinase inhibitor LY2157299 monohydrate

Oncology Letters

Volumn 9, Issue 6, 2015, Pages 2442-2448

  Sepulveda Sanchez, Juan ^a   Ramos, Ana ^a   Hilario, Amaya ^a   De Velasco, Guillermo ^a   Castellano, Daniel ^a   De La Torre, Marta Garcia ^b   Rodon, Jordi ^c   Lahn, Michael F ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b ELI LILLY AND COMPANY   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Combination therapy; Glioblastoma; Lomustine; Magnetic resonance imaging; Transforming growth factor inhibitor LY2157299

Indexed keywords

GALUNISERTIB; LOMUSTINE;

ARTICLE; BLOOD VESSEL PERMEABILITY; BRAIN PERFUSION; CANCER INHIBITION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; GLIOBLASTOMA; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 84930005881     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3106     Document Type: Article

References (36)

1. Massagué J, Blain SW and Lo RS: TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309, 2000.
2. Hughes C, Bauer E and Roberts AP: Spread of R-plasmids among Escherichia coli causing urinary tract infections. Antimicrob Agents Chemother 20: 496-502, 1981.
3. Bruna A, Darken RS, Rojo F, et al: High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11: 147-160, 2007.
4. Peñuelas S, Anido J, Prieto-Sánchez RM, et al: TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15: 315-327, 2009.
5. Sawyer JS, Beight DW, Britt KS, et al: Synthesis and activity of new aryl-and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg Med Chem Lett 14: 3581-3584, 2004.
6. Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, et al: TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell 18: 655-668, 2010.
7. Li HY, Wang Y, Yan L, et al: Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines. Bioorg Med Chem Lett 14: 3585-3588, 2004.
8. Anderton MJ, Mellor HR, Bell A, et al: Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol 39: 916-924, 2011.
9. Bueno L, de Alwis DP, Pitou C, et al: Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 44: 142-150, 2008.
10. Gueorguieva I, Cleverly AL, Stauber A, et al: Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. Br J Clin Pharmacol 77: 796-807, 2014.
11. Vredenburgh JJ, Desjardins A, Herndon JE II, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-1259, 2007.
12. Lenato GM and Guanti G: Hereditary Haemorrhagic Telangiectasia (HHT): Genetic and molecular aspects. Curr Pharm Des 12: 1173-1193, 2006.
13. Lechleider RJ, Ryan JL, Garrett L, et al: Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion. Dev Biol 240: 157-167, 2001.
14. Li F, Lan Y, Wang Y, et al: Endothelial Smad4 maintains cerebrovascular integrity by activating N-cadherin through cooperation with Notch. Dev Cell 20: 291-302, 2011.
15. Dickinson ME, Selleck MA, McMahon AP and Bronner-Fraser M: Dorsalization of the neural tube by the non-neural ectoderm. Development 121: 2099-2106, 1995.
16. Oshima M, Oshima H and Taketo MM: TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 179: 297-302, 1996.
17. Goumans MJ, Valdimarsdottir G, Itoh S, et al: Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21: 1743-1753, 2002.
18. Gerstner ER, Sorensen AG, Jain RK and Batchelor TT: Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol 21: 728-735, 2008.
19. Pechman KR, Donohoe DL, Bedekar DP, et al: Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume. Magn Reson Med 68: 1266-1272, 2012.
20. Sorensen AG, Emblem KE, Polaskova P, et al: Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72: 402-407, 2012.
21. Hilario A, Ramos A, Perez-Nuñez A, et al: The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. AJNR Am J Neuroradiol 33: 701-707, 2012.
22. Maeda M, Itoh S, Kimura H, et al: Tumor vascularity in the brain: Evaluation with dynamic susceptibility-contrast MR imaging. Radiology 189: 233-238, 1993.
23. Aronen HJ, Gazit IE, Louis DN, et al: Cerebral blood volume maps of gliomas: Comparison with tumor grade and histologic findings. Radiology 191: 41-51, 1994.
24. Donahue KM, Krouwer HG, Rand SD, et al: Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 43: 845-853, 2000.
25. Law M, Oh S, Babb JS, et al: Low-grade gliomas: Dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging -prediction of patient clinical response. Radiology 238: 658-667, 2006.
26. Sugahara T, Korogi Y, Tomiguchi S, et al: Posttherapeutic intraaxial brain tumor: The value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 21: 901-909, 2000.
27. Rodon Ahnert J, Baselga J, Calvo E, et al: First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. J Clin Oncol 29: abstract 3011, 2011.
28. Azaro A, Baselga J, Sepúlveda JM, et al: The oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study. J Clin Oncol 30: abstract 2042, 2012.
29. Trotti A, Colevas AD, Setser A, et al: CTCAE v3.0: development of a comprenhensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003.
30. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
31. Macdonald DR, Cascino TL, Schold SC Jr and Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990.
32. Vidiri A, Pace A, Fabi A, et al: Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: Preliminary results by a quantitative evaluation. J Exp Clin Cancer Res 31: 33, 2012.
33. Thompson G, Mills SJ, Coope DJ, et al: Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours. Br J Radiol 84: S127-S144, 2011.
34. Jenkinson MD, Smith TS, Joyce KA, et al: Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 48: 703-713, 2006.
35. Kappelle AC, Postma TJ, Taphoorn MJ, et al: PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56: 118-120, 2001.
36. Wick W, Puduvalli VK, Chamberlain MC, et al: Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28: 1168-1174, 2010.